Latest Mecasermin rinfabate Stories
- 24 patients now recruited into the trial TOORAK, Australia, March 21, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP") is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial. Following from the positive results achieved from the interim...
- A stinking tobacco.
- Offal; waste animal product; organic matter unfit for consumption.